Go Pro
→ Major Buy Alert Issued for October 31st (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$66.11
+2.0%		$81.26
$34.61
▼
$95.49
$9.29B1.32.29 million shs205,762 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$10.32
+11.2%		$7.95
$1.95
▼
$12.43
$10.92B0.0220.67 million shs6.39 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$328.98
+1.1%		$343.15
$179.16
▼
$382.54
$9.73B0.5328,690 shs37,676 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.07
-0.4%		$25.69
$21.02
▼
$42.21
$2.88B0.11.13 million shs68,199 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-1.01%-1.94%-21.69%-22.86%+85.06%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-1.69%+7.41%+17.92%-1.69%+274.19%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-2.18%-5.70%-10.59%-13.27%+81.12%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-0.66%+6.24%-3.05%-30.63%-17.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$66.11
+2.0%		$81.26
$34.61
▼
$95.49
$9.29B1.32.29 million shs205,762 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$10.32
+11.2%		$7.95
$1.95
▼
$12.43
$10.92B0.0220.67 million shs6.39 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$328.98
+1.1%		$343.15
$179.16
▼
$382.54
$9.73B0.5328,690 shs37,676 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.07
-0.4%		$25.69
$21.02
▼
$42.21
$2.88B0.11.13 million shs68,199 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-1.01%-1.94%-21.69%-22.86%+85.06%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-1.69%+7.41%+17.92%-1.69%+274.19%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-2.18%-5.70%-10.59%-13.27%+81.12%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-0.66%+6.24%-3.05%-30.63%-17.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.64
Moderate Buy$98.3148.71% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.86
Moderate Buy$14.2037.65% Upside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$377.2014.66% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.73106.59% Upside

Current Analyst Ratings Breakdown

Latest NAMS, KRYS, IBRX, and ARWR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/24/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
9/24/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$441.00
9/24/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$74.00
9/24/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$441.00
9/23/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/21/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$392.00 ➝ $400.00
9/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$108.00
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
9/1/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/31/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$100.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M11.23$0.12 per share548.16$3.64 per share18.16
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M96.51N/AN/A($0.51) per share-20.23
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M25.02$7.21 per share45.62$42.06 per share7.82
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M127.88N/AN/A$5.97 per share4.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.25N/AN/AN/A-47.79%-60.06%-17.37%11/24/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.97N/AN/AN/A-598.55%N/A-51.65%11/3/2026 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.9841.2135.91N/A54.82%19.34%17.65%11/2/2026 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)

Latest NAMS, KRYS, IBRX, and ARWR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q3 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.23-$1.36-$0.13-$1.36$44.17 million$75.25 million
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.70 million$51.24 million
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.70$1.79+$0.09$1.79$120.93 million$119.22 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.77
5.90
5.90
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.72
5.70
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
8.32
7.96
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
711140.86 million135.79 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion359.28 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
29529.60 million25.72 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable

Recent News About These Companies

NewAmsterdam Pharma: Can Obicetrapib's Data In Diabetes And Metabolic Syndrome Bring Back The Mojo?
September 30 at 2:45 PM  |  rttnews.comhttps://www.rttnews.com/3695347/newamsterdam-pharma-can-obicetrapib-s-data-in-diabetes-and-metabolic-syndrome-bring-back-the-mojo.aspx
NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease
September 29 at 6:13 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-doses-first-participant-142330891.html
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29 at 6:13 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/newamsterdam-pharma-doses-first-participant-in-phase-2b-spinoza-trial-evaluating-obicetrapib-in-preclinical-alzheimer-s-disease-1036581179
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
September 29 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370754/0/en/newamsterdam-pharma-doses-first-participant-in-phase-2b-spinoza-trial-evaluating-obicetrapib-in-preclinical-alzheimer-s-disease.html
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 5.8% - What's Next?
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-newamsterdam-pharma-nasdaq-nams-stock-price-up-58-whats-next-2026-09-28/
First global regulatory approval of obicetrapib
September 28, 2026  |  thepharmaletter.comT
NewAmsterdam Pharma Company NV (NAMS)
September 27, 2026  |  za.investing.comhttps://za.investing.com/equities/frazier-lifesciences-acquisition-news
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)
September 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RDNT/pressreleases/4754037/analysts-are-bullish-on-top-healthcare-stocks-ptc-therapeutics-ptct-newamsterdam-pharma-company-nams/
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
September 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/newamsterdam-pharma-nams-wins-eu-approvals-can-cholesterol-pills-drive-royalties-1841803/
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
September 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NAMS/pressreleases/4737581/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn/
Newamsterdam Pharma Company N.V. and Menarini Group Receive European Commission Approval for Ubeslo and Evlarco
September 22, 2026  |  marketscreener.comM
NewAmsterdam Wins First Global Approval For Obicetrapib Cholesteorl Treatments
September 21, 2026  |  rttnews.comhttps://www.rttnews.com/3692646/newamsterdam-wins-first-global-approval-for-obicetrapib-cholesteorl-treatments.aspx
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/newamsterdam-pharma-gets-eu-approval-140956912.html
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - Here's Why
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-newamsterdam-pharma-nasdaq-nams-sees-strong-trading-volume-heres-why-2026-09-21/
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/21/3365512/0/en/newamsterdam-pharma-and-menarini-group-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination.html
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run
September 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/newamsterdam-pharma-nams-stock-looks-041835524.html
Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Buys $226,500.00 in Stock
September 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nams-insider-buying-and-selling-2026-09-16/
NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 12-Month Low - Here's Why
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-newamsterdam-pharma-nasdaq-nams-reaches-new-12-month-low-heres-why-2026-09-16/
Insider Buying: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Acquires 10,000 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-buying-newamsterdam-pharma-nasdaq-nams-ceo-acquires-10000-shares-of-stock-2026-09-15/
Squarepoint Ops LLC Purchases 49,005 Shares of NewAmsterdam Pharma Company N.V. $NAMS
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-purchases-49005-shares-of-newamsterdam-pharma-company-nv-nams-2026-09-14/
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Rating of "Moderate Buy" by Brokerages
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-newamsterdam-pharma-company-nv-nasdaq-nams-given-consensus-rating-of-moderate-buy-by-brokerages-2026-09-12/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
By Jeffrey Neal Johnson | October 2, 2026
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$66.11 +1.32 (+2.03%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$10.32 +1.04 (+11.16%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$328.98 +3.67 (+1.13%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$24.07 -0.09 (-0.37%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas